The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin.
作者： P. FONTANA , P. ALBERTS , K. S. SAKARIASSEN , H. BOUNAMEAUX , J.-P. MEYER
DOI: 10.1111/J.1538-7836.2011.04446.X
关键词:
摘要:
core.ac.uk
sci-hub.se 参考文章(9)
IA Reilly, GA FitzGerald, Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. ,vol. 69, pp. 180- 186 ,(1987) , 10.1182/BLOOD.V69.1.180.BLOODJOURNAL691180
Kjell S. Sakariassen, Reto Muggli, Hans R. Baumgartner, [5] Measurements of platelet interaction with components of the vessel wall in flowing blood Methods in Enzymology. ,vol. 169, pp. 37- 70 ,(1989) , 10.1016/0076-6879(89)69049-0
Angelika G. Börsch-Haubold, Sophie Pasquet, Steve P. Watson, Direct Inhibition of Cyclooxygenase-1 and -2 by the Kinase Inhibitors SB 203580 and PD 98059 SB 203580 ALSO INHIBITS THROMBOXANE SYNTHASE Journal of Biological Chemistry. ,vol. 273, pp. 28766- 28772 ,(1998) , 10.1074/JBC.273.44.28766
P. Fontana, J.-L. Reny, New antiplatelet strategies in atherothrombosis and their indications. European Journal of Vascular and Endovascular Surgery. ,vol. 34, pp. 10- 17 ,(2007) , 10.1016/J.EJVS.2007.01.004
Séverine Roger, Marc Pawlowski, Aı̈da Habib, Martine Jandrot-Perrus, Jean-Philippe Rosa, Marijke Bryckaert, Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation FEBS Letters. ,vol. 556, pp. 227- 235 ,(2004) , 10.1016/S0014-5793(03)01430-3
Cheng Yung-Chi, William H. Prusoff, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology. ,vol. 22, pp. 3099- 3108 ,(1973) , 10.1016/0006-2952(73)90196-2
Laurent P. Audoly, Bianca Rocca, Jean-Etienne Fabre, Beverly H. Koller, Dennis Thomas, Alex L. Loeb, Thomas M. Coffman, Garret A. FitzGerald, Cardiovascular Responses to the Isoprostanes iPF2α-III and iPE2-III Are Mediated via the Thromboxane A2 Receptor In Vivo Circulation. ,vol. 101, pp. 2833- 2840 ,(2000) , 10.1161/01.CIR.101.24.2833
Kjell S Sakariassen, Peteris Alberts, Pierre Fontana, Jessica Mann, Henri Bounameaux, Alexandra Santana Sorensen, Effect of pharmaceutical interventions targeting thromboxane receptors and thromboxane synthase in cardiovascular and renal diseases Future Cardiology. ,vol. 5, pp. 479- 493 ,(2009) , 10.2217/FCA.09.33
Antonio J. Cayatte, Yue Du, Jennifer Oliver-Krasinski, Gilbert Lavielle, Tony J. Verbeuren, Richard A. Cohen, The Thromboxane Receptor Antagonist S18886 but Not Aspirin Inhibits Atherogenesis in Apo E–Deficient Mice: Evidence That Eicosanoids Other Than Thromboxane Contribute to Atherosclerosis Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 20, pp. 1724- 1728 ,(2000) , 10.1161/01.ATV.20.7.1724